News

Prevail Therapeutics and Lonza Pharma & Biotech will collaborate in the development and production of Prevail’s PR001 gene therapy for children with type 2 Gaucher disease and for select patients with Parkinson’s disease, the companies announced. Prevail is looking to start recruiting patients with type 2, or pediatric…

Mobile phone-based monitoring may allow for better measurement of how Gaucher disease affects the lives of those who have it, a new pilot study reports. The investigators suggest that such monitoring also might allow healthcare providers to improve personalized care, and could be useful in research. Titled “…

What began in the early 1990s as an informal gathering of seven European patient groups in the Italian port of Trieste has evolved into the world’s largest charity for Gaucher disease. The International Gaucher Alliance (IGA) — founded by France, Germany, Great Britain, Israel, Italy, and the Netherlands…

Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar, MD, chairman of NORD’s board of directors. “The pace of discovery in rare diseases has gone from brisk to hypersonic,” Summar told BioNews Services, publisher…